AbbVie
|
Not yet recruiting
|
Phase 2|Phase 3
|
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
|
Hypothyroidism
|
Armour Thyroid|Levothyroxine
|
2024-03-27
|
2024-04-03
|
|
2028-06-03
|
Anticipated
|
2800
|
AbbVie
|
Not yet recruiting
|
Phase 3
|
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
|
Crohn's Disease
|
Upadacitinib
|
2024-03-19
|
2024-03-27
|
|
2034-12-20
|
Anticipated
|
110
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
|
Glabellar Lines
|
AGN-151586|Placebo
|
2024-03-07
|
2024-04-26
|
|
2025-03-22
|
Anticipated
|
160
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity in Adult Participants With Migraine
|
Migraine
|
Atogepant|Placebo for Atogepant
|
2024-01-28
|
2024-03-25
|
|
2025-11-30
|
Anticipated
|
1300
|
AbbVie
|
Recruiting
|
Phase 2|Phase 3
|
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|
Non-Small Cell Lung Cancer
|
Livmoniplimab|Budigalimab|Pembrolizumab|Pemetrexed|Cisplatin|Carboplatin
|
2024-01-24
|
2024-04-26
|
|
2031-10-08
|
Anticipated
|
840
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
|
Follicular Lymphoma (FL)
|
Epcoritamab|Prednisone|Rituximab|Lenalidomide|Doxorubicin|Vincristine
|
2023-12-20
|
2024-04-02
|
|
2037-05-19
|
Anticipated
|
900
|
AbbVie
|
Active, not recruiting
|
Phase 3
|
A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants
|
Forehead Lines
|
BOTOX|Placebo
|
2023-12-08
|
2024-04-17
|
|
2024-09-18
|
Anticipated
|
140
|
AbbVie
|
Not yet recruiting
|
Phase 3
|
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
|
Multiple Myeloma
|
ABBV-383|Carfilzomib|Pomalidomide|Elotuzumab|Selinexor|Bortezomib
|
2023-11-28
|
2023-12-22
|
|
2027-12-06
|
Anticipated
|
380
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants
|
Masseter Muscle Prominence
|
BOTOX|Placebo for BOTOX
|
2023-11-14
|
2024-02-20
|
|
2026-01-10
|
Anticipated
|
250
|
AbbVie
|
Enrolling by invitation
|
Phase 3
|
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
|
Vitiligo
|
Upadacitinib|Placebo
|
2023-11-01
|
2024-03-28
|
|
2028-02-05
|
Anticipated
|
540
|
AbbVie
|
Recruiting
|
Phase 2|Phase 3
|
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
|
Hepatocellular Carcinoma
|
Livmoniplimab|Budigalimab|Durvalumab|Atezolizumab|Bevacizumab|Tremelimumab
|
2023-10-26
|
2024-04-01
|
|
2030-09-06
|
Anticipated
|
660
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
|
Juvenile Psoriatic Arthritis
|
Adalimumab|Risankizumab
|
2023-10-20
|
2024-04-09
|
|
2028-10-07
|
Anticipated
|
40
|
AbbVie
|
Not yet recruiting
|
Phase 3
|
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
|
Non-Small Cell Lung Cancer
|
Telisotuzumab Vedotin|Osimertinib|Cisplatin|Carboplatin|Pemetrexed
|
2023-10-17
|
2023-10-23
|
|
2028-04-11
|
Anticipated
|
250
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
|
Masseter Muscle Prominence
|
BOTOX|Placebo
|
2023-09-29
|
2024-04-11
|
|
2025-11-25
|
Anticipated
|
248
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
|
Crohn's Disease
|
Risankizumab SC|Placebo for risankizumab
|
2023-09-26
|
2024-04-25
|
|
2028-02-23
|
Anticipated
|
276
|
AbbVie
|
Recruiting
|
Phase 2|Phase 3
|
A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds
|
Nasolabial Folds
|
No-Treatment Control|HAC 20L
|
2023-08-25
|
2024-01-23
|
|
2026-08-19
|
Anticipated
|
255
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
|
Alopecia Areata
|
Upadacitinib|Placebo
|
2023-08-22
|
2024-04-26
|
|
2028-01-22
|
Anticipated
|
1500
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
|
Crohn's Disease
|
Risankizumab|Risankizumab
|
2023-08-10
|
2024-04-19
|
|
2029-04-28
|
Anticipated
|
110
|
AbbVie
|
Recruiting
|
Phase 3
|
ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars
|
Atrophic Acne Scars
|
ELAPR002f Injectable Gel|Saline Control
|
2023-08-10
|
2024-03-26
|
|
2025-08-18
|
Anticipated
|
156
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
|
Hidradenitis Suppurativa
|
Upadacitinib|Placebo
|
2023-05-26
|
2024-03-06
|
|
2027-08-01
|
Anticipated
|
1328
|
AbbVie
|
Completed
|
Phase 3
|
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
|
Dry Eye Syndrome
|
ABBV-444
|
2023-05-24
|
2023-12-12
|
|
2023-10-06
|
Actual
|
40
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
|
Migraine
|
Atogepant|Placebo for Atogepant
|
2023-05-08
|
2023-11-14
|
|
2025-05-28
|
Anticipated
|
520
|
AbbVie
|
Recruiting
|
Phase 3
|
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
|
Systemic Lupus Erythematosus
|
Upadacitinib|Placebo
|
2023-04-25
|
2024-04-26
|
|
2027-10-31
|
Anticipated
|
1000
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants
|
Facial Volume Deficit
|
HAC 22L
|
2023-04-06
|
2023-10-02
|
|
2026-09-18
|
Anticipated
|
259
|
AbbVie
|
Recruiting
|
Phase 3
|
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
|
Rheumatoid Arthritis
|
Upadacitinib|Adalimumab|Upadacitinib Matching Placebo|Adalimumab Matching Placebo
|
2023-04-04
|
2024-04-26
|
|
2026-08-15
|
Anticipated
|
480
|
AbbVie
|
Recruiting
|
Phase 3
|
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
|
Ulcerative Colitis
|
Upadacitinib
|
2023-03-13
|
2024-04-19
|
|
2033-10-31
|
Anticipated
|
110
|
AbbVie
|
Recruiting
|
Phase 3
|
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
|
Migraine
|
Atogepant|Placebo for Atogepant|Topiramate|Placebo for Topiramate
|
2023-02-20
|
2024-04-23
|
|
2026-06-29
|
Anticipated
|
520
|
AbbVie
|
Active, not recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants
|
Neck Lines
|
JUVÉDERM® VOLITE™|Control
|
2023-02-14
|
2023-12-01
|
|
2024-12-15
|
Anticipated
|
159
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Episodic Migraine
|
Atogepant|Placebo-Matching Atogepant
|
2023-01-26
|
2024-04-22
|
|
2028-05-04
|
Anticipated
|
450
|
AbbVie
|
Enrolling by invitation
|
Phase 3
|
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine
|
Episodic Migraine
|
Atogepant
|
2023-01-24
|
2024-02-08
|
|
2029-11-16
|
Anticipated
|
250
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
|
Functional Constipation (FC)|Chronic Idiopathic Constipation (CIC)
|
Linaclotide|Placebo for Linaclotide
|
2022-12-02
|
2024-04-25
|
|
2025-11-14
|
Anticipated
|
116
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Juvenile Idiopathic Arthritis
|
Upadacitinib|Tocilizumab
|
2022-11-07
|
2024-04-26
|
|
2029-06-19
|
Anticipated
|
90
|
AbbVie
|
Active, not recruiting
|
Phase 3
|
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
|
Atopic Dermatitis
|
Upadacitinib|Dupilumab
|
2022-10-31
|
2024-04-24
|
|
2024-08-08
|
Anticipated
|
880
|
AbbVie
|
Recruiting
|
Phase 3
|
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
|
Diffuse Large B-Cell Lymphoma
|
Epcoritamab|Cyclophosphamide|Rituximab|Vincristine|Doxorubicin|Prednisone
|
2022-10-12
|
2024-04-09
|
|
2029-12-30
|
Anticipated
|
900
|
AbbVie
|
Active, not recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth
|
Perioral Lines
|
JUVÉDERM® VOLITE™|Control
|
2022-07-08
|
2023-09-07
|
|
2024-10-27
|
Anticipated
|
198
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
|
Autism Spectrum Disorder
|
Cariprazine|Placebo
|
2022-06-28
|
2024-04-23
|
|
2024-11-25
|
Anticipated
|
152
|
AbbVie
|
Recruiting
|
Phase 3
|
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
|
Open-Angle Glaucoma
|
XEN45 (Glaucoma Gel Stent)
|
2022-06-06
|
2024-04-15
|
|
2025-08-15
|
Anticipated
|
65
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
|
Follicular Lymphoma (FL)
|
Epcoritamab|Rituximab|Lenalidomide
|
2022-06-03
|
2024-04-09
|
|
2030-06-16
|
Anticipated
|
500
|
AbbVie
|
Recruiting
|
Phase 3
|
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
|
Schizophrenia
|
Cariprazine|Placebo
|
2022-05-06
|
2024-04-03
|
|
2034-08-11
|
Anticipated
|
250
|
AbbVie
|
Not yet recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
|
Ulcerative Colitis (UC)
|
Mesalamine|Placebo
|
2022-03-31
|
2024-03-29
|
|
2026-07-19
|
Anticipated
|
80
|
AbbVie
|
Active, not recruiting
|
Phase 3
|
A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants
|
Neck Lines
|
VOLITE XC|VOLITE XC
|
2022-03-31
|
2023-08-30
|
|
2024-12-31
|
Anticipated
|
159
|
AbbVie
|
Recruiting
|
Phase 3
|
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
|
AMD|nAMD|Wet Age-related Macular Degeneration|wAMD|WetAMD|CNV
|
RGX-314 Dose 1|RGX-314 Dose 2|Aflibercept (EYLEA®)
|
2022-01-28
|
2023-08-21
|
|
2025-12-01
|
Anticipated
|
465
|
AbbVie
|
Recruiting
|
Phase 3
|
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
|
Chronic Migraine
|
Atogepant
|
2022-01-19
|
2024-03-12
|
|
2024-12-27
|
Anticipated
|
75
|